CORT Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 21.47%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Johnson & Johnson's return on equity of 33.27%.

Corcept Therapeutics, Inc. has a consensus price target of $127.20, signalling upside risk potential of 53.9%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.8%. Given that Corcept Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Corcept Therapeutics, Inc. is more attractive than Johnson & Johnson.

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.48% to investors and pays a quarterly dividend of $1.30 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Johnson & Johnson's net income of $5.2B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 94.44x while Johnson & Johnson's PE ratio is 20.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.33x versus 5.46x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Theravance Biopharma, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 18.08%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.

Corcept Therapeutics, Inc. has a consensus price target of $127.20, signalling upside risk potential of 53.9%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 41.8%. Given that Corcept Therapeutics, Inc. has higher upside potential than Theravance Biopharma, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Theravance Biopharma, Inc..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.143, suggesting its less volatile than the S&P 500 by 85.696%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are larger than Theravance Biopharma, Inc. quarterly revenues of $20M. Corcept Therapeutics, Inc.'s net income of $19.4M is higher than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 94.44x while Theravance Biopharma, Inc.'s PE ratio is 33.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.33x versus 11.82x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics Corp. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 42.36%. Corcept Therapeutics, Inc.'s return on equity of 16% beat United Therapeutics Corp.'s return on equity of 19.2%.

Corcept Therapeutics, Inc. has a consensus price target of $127.20, signalling upside risk potential of 53.9%. On the other hand United Therapeutics Corp. has an analysts' consensus of $518.25 which suggests that it could grow by 2.19%. Given that Corcept Therapeutics, Inc. has higher upside potential than United Therapeutics Corp., analysts believe Corcept Therapeutics, Inc. is more attractive than United Therapeutics Corp..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison United Therapeutics Corp. has a beta of 0.861, suggesting its less volatile than the S&P 500 by 13.874%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. United Therapeutics Corp. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than United Therapeutics Corp. quarterly revenues of $799.5M. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than United Therapeutics Corp.'s net income of $338.7M. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 94.44x while United Therapeutics Corp.'s PE ratio is 19.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.33x versus 7.82x for United Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of 9.32% compared to Corcept Therapeutics, Inc.'s net margin of 34.76%. Corcept Therapeutics, Inc.'s return on equity of 16% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Corcept Therapeutics, Inc. has a consensus price target of $127.20, signalling upside risk potential of 53.9%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 6.27%. Given that Corcept Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Corcept Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Corcept Therapeutics, Inc. has a beta of 0.197, which suggesting that the stock is 80.287% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.

Corcept Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Corcept Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Corcept Therapeutics, Inc. quarterly revenues are $207.6M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Corcept Therapeutics, Inc.'s net income of $19.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Corcept Therapeutics, Inc.'s price-to-earnings ratio is 94.44x while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Corcept Therapeutics, Inc. is 13.33x versus 10.22x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.